Key Takeaways
- • The primary source is a JD Supra republication of a McDermott Will & Schulte piece titled "Beyond growth: New priorities for healthcare private equity," which frames healthcare PE as a compelling market for sponsors and operators able to convert growth opportunities into durable earnings.
- • The available text is limited to a publisher summary and site navigation, so specific deal values, fund figures, and named examples cannot be verified from this source.
- • The headline signals a shift in investment priorities in healthcare private equity away from growth-led theses toward earnings durability and operational execution.
Summary
A McDermott Will & Schulte article, republished on JD Supra and dated October 29, 2026, examines new priorities for healthcare private equity. According to the publisher summary, healthcare PE "remains a compelling market for sponsors and operators that can turn growth opportunities into durable earnings," a framing that positions earnings quality and sustainability as central to value creation in the sector.
The headline, "Beyond growth," suggests the piece argues that growth alone is no longer sufficient as the organizing thesis for healthcare private equity investments. For institutional allocators and fund managers, this points to a focus on converting top-line expansion into recurring, durable cash earnings rather than relying on multiple expansion or unproven growth.
The source page available for this summary contains only the publisher abstract and JD Supra navigation text, so the article's specific analysis, deal examples, regulatory considerations, and quantitative data are not reflected here. Readers seeking detail on the particular priorities identified should consult the original McDermott Will & Schulte publication.
The headline, "Beyond growth," suggests the piece argues that growth alone is no longer sufficient as the organizing thesis for healthcare private equity investments. For institutional allocators and fund managers, this points to a focus on converting top-line expansion into recurring, durable cash earnings rather than relying on multiple expansion or unproven growth.
The source page available for this summary contains only the publisher abstract and JD Supra navigation text, so the article's specific analysis, deal examples, regulatory considerations, and quantitative data are not reflected here. Readers seeking detail on the particular priorities identified should consult the original McDermott Will & Schulte publication.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.